The potential of nanotechnology for cancer research has been tremendous for the medical field, leading to significant improvements in diagnostics and therapeutics.
Nanoparticles and nanomaterials with remarkable physiochemical properties have been used for applications such as early cancer detection, tumor imaging and drug delivery. This article will provide an overview of how nanotechnology has assisted with breakthroughs in cancer research.
Background
In 2020, the World Health Organization (WHO) reported cancer as the leading cause of mortality, with devastating global statistics such as 10 million deaths.
Nanosynth Group plc (LON:NNN) is focused on the synthesis and application of nanoparticles. The group uses a patented process developed by Dr Cave at Nottingham Trent University. It has three subsidiaries; Pharm 2 Farm Ltd, nanosynth ltd and Cloudveil.